Definium Therapeutics provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses.
Definium Therapeutics has raised $805.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
Definium Therapeutics's investors include Janus Henderson Investors, Great Point Partners, CIBC, Ally Bridge Group, Commodore Capital.
Definium Therapeutics is headquartered in New York, United States.
Definium Therapeutics provides psychedelic-inspired medicines and therapies for substance abuse disorders and other mental illnesses.
Definium Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Definium Therapeutics — Funding & Investors." VCBacked, June 23, 2026, https://www.vcbacked.co/company/definium-therapeutics. Accessed November 13, 2026.
VCBacked. (2026). Definium Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/definium-therapeutics
{{cite web |title=Definium Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/definium-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Definium Therapeutics? Request a listing update